- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
158
(r ¼ 0.44) correlated (po0.01) with the neuroretinal rim area (r ¼ 0.44). RFonh showed a weak, borderline significant (po0.10) correlation (r ¼ 0.30) with pattern ERG amplitudes and perimetric mean deviation. From this study, it was concluded that RFonh is abnormally reduced in OHT and EOAG patients, indicating an impairment of luminance (M-cellular)-mediated vasoactivity. Flicker-evoked Fonh changes appear to be only weakly correlated with functional indicators of neural damage, suggesting that a loss of neurovascular coupling of the optic nerve head may occur independently of neural activity loss early in the disease process.
Discussion
FLDF and neurovascular coupling in humans
Previous studies in animals have demonstrated a tight correlation between local RFonh and neuronal activity response, the latter obtained from the flicker-induced changes in the electrical signal (Riva and Buerk, 1998) and K+ ion concentration (Buerk et al., 1995), both measured at the surface of the optic disk. In humans, luminance and heterochromatic flicker stimulation generate a RFonh that displays characteristics comparable to those of ganglion cell spiking activity evoked by the same stimuli, when RFonh is plotted as a function of frequency, modulation depth, and relative chromaticity (Riva et al., 2001). Although these findings had suggested the existence of a coupling between vasoand neuronal activity, the exact relationship between both physiological activities remained to be established. With this goal in mind, and since noninvasive methods to measure local activity at the optic nerve rim are not yet available, the 1F and 2F components of the flicker ERG and the simultaneously recorded RFonh were correlated. Although the pattern ERG, which is generated mainly by ganglion cell activity, would appear to be the most appropriate stimulus to correlate activity and RFonh in humans, the components of the F-ERG were chosen because of the substantial amount of data available from humans. In addition, the hypothesis
of an association between RFonh and the 1F and 2F harmonics of the flicker ERG was justified
based on the origin of these components of retinal neural activity.
The results of investigations in the normal human eye (Falsini et al., 2002) indicated that, under specific experimental conditions, the stimu-
lus-evoked changes in RFonh are similar and significantly correlated to the changes in the flicker
ERG harmonic components. In particular, the associations were the most significant (a) when (Fig. 8) the temporal frequency of the stimulus was changed in the condition of heterochromatic red– green equiluminant flicker; (b) when the mean illuminance was varied for a green illuminance flicker; and (c) when the color ratio, r, was varied for the heterochromatic R-G flicker. In case (a), RFonh was correlated with both 1F and 2F amplitudes. In the others, RFonh was correlated only with the 2F amplitude.
The significant correlation found between RFonh and each of 1F and 2F amplitudes for the case of R-G equiluminant flicker responses recorded as a function of temporal frequency, as well as between
RFonh and 2F amplitudes for R-G flicker responses as a function of r, suggests a coupling
arising from the pooled activity of the middleand long-wavelength sensitive cones. Given the retinal origin of the flicker ERG 2F, the present findings provide support to the hypothesis that blood flow changes recorded at the ONH in response to flicker stimulation parallel the corresponding changes in the neural function of the inner retina. Under some experimental conditions (chromatic flicker modulated at different temporal frequencies), however, RFonh changes may also be similar to changes in the 1F amplitude, implying common properties of optic nerve vasoand neural activity changes in the middle retina (i.e. ON and OFF bipolar cells).
In the case of pure luminance flicker experiments, when changing temporal frequency, no significant association was found between RFonh and both components’ amplitudes. A possible physiological basis for this finding is that the generators underlying RFonh and ERG response to luminance flicker may differ depending on flicker frequency. Multiple generators for both responses, whose relative contribution changes according to
stimulus frequency, may obscure the correlation when measurements are obtained over a range of frequencies. On the other hand, it is possible that the blood flow and neural responses to a specific stimulus frequency, i.e. the luminance flicker at 10 Hz, share common generators in the inner retina, thus revealing the association between
RFonh and ERG 2F amplitude. In contrast, the R-G heterochromatic flicker reveals a significant
coupling between RFonh and both 1F and 2F amplitudes, suggesting a contribution from both retinal layers to the coupling between the neural and vascular responses.
Although several previous studies have suggested a neurovascular coupling in the human retina (Scheiner et al., 1994; Riva et al., 1995), direct evidence of it has not been provided in the past. The observed correlations may not directly prove an effect of retinal neural activity on blood flow measured at the optic disk. It is however reasonable to suggest that the pooled response of neural generators underlying the 1F and 2F components may induce a vaso-active mechanism resulting in a corresponding blood flow change. Putative mediators underlying this neurovascular response have been discussed in detail in previous reports (Buerk et al., 1995, 1996; Kondo et al., 1997; Riva and Buerk, 1998), the most prominent being nitric oxide (NO). The present findings support the hypothesis that the strength of neurovascular coupling may be dependent upon the type of flicker stimulus. From the data shown in Fig. 8 it can be concluded that both luminance and chromatic flicker may be appropriate to study the coupling between RFonh and 2F amplitude, whereas the chromatic equiluminant stimulus appears to be more suitable for investigating the association between RFonh and 1F.
Comments on clinical application of FLDF in glaucoma
The data reviewed here demonstrated that RFonh is diminished in both OHT and EOAG patients compared to normal controls. The group-averaged time course of the flicker-induced increase in Fonh in EOAG was not significantly different from that found in the normal subjects. Presumably, in the
159
EOAG patients the flicker-induced vasodilatation in the apparently healthy rim tissue of the anterior optic nerve has a normal temporal evolution.
Our results strongly suggest that the decrease in RFonh reflects an altered ganglion cell activity response to the flicker. Nevertheless, other possible explanations of this decrease need to be addressed to. One possibility could be that resting blood flow in the rim tissue of the OHT and EOAG patients could be too low in comparison with the amount of tissue it supplies to satisfy the metabolic needs. Consequently, it would be unable to fully respond to the additional stress evoked by the flicker stimulation. However, the lack of correlation between RFonh and Fonh (Riva et al., 2004b) goes against this hypothesis. Another possibility is that in the EOAG group, because the nerve fiber layer is thinner than in the normal control and OHT groups, the choroid would contribute more to the LDF signal. This is unlikely since the markedly higher flow velocities in the choriocapillaris did not result in a significantly greater RVelonh at rest in the EOAG compared to the control group. Furthermore, RFonh was also found to be reduced in the OHT group, although the nerve fiber layer thickness in this group was not significantly different from the control group.
Studies in the human eye using a range of flicker frequencies and modulations suggest that the RFonh loss observed in our patients when using a 15 Hz luminance flicker occurs predominantly at the level of the ganglion cell M-cellular pathway (Riva et al., 2001; Falsini et al., 2002). This hypothesis agrees with the large body of anatomical evidence indicating that, in early glaucoma, large ganglion cells, subserving primarily the M-cellular pathway, are selectively or predominantly damaged (Quigley et al., 1989; Glovinski et al., 1991; Kerrigan-Baumrind et al., 2000).
Patients’ RFonh, in contrast, were poorly correlated with functional indicators of early damage, such as pattern ERG and Humphrey perimetric indices. Thus, the data obtained from the OHT patients show that, in some of these patients, the
pattern ERG was normal whereas RFonh was substantially diminished. In other OHT patients,
the opposite was found. This poor correlation may be related to the inherent variability of the
160
techniques employed in this study, or, alternatively, may reflect an altered neurovascular coupling in early stages of diseases. Alteration of the neurovascular coupling could occur at various points of the chain of events coupling the activity to the local vasodilatation (Zonta et al., 2003), such as the flicker-induced release of NO, K+, or other substances (Buerk et al., 1996; Kondo et al., 1997; Zonta et al., 2003), the glutamate release from axonal terminals, the activation of astrocytes and subsequent release of vasodilating products and possibly others. Clearly, future work should be aimed at elucidating this important question.
RFonh was positively correlated with neuroretinal rim area when the two groups of patients were pooled. In EOAG patients, although this correlation did not reach significance, possibly because of the low number of patients, both neuro-
retinal rim area and RFonh were smaller in the average than the corresponding values in OHT
and normal controls. It has been previously shown that a reduction in neuro-retinal rim area, together with an increase in cup/disk area ratio and cup shape measure, may be highly accurate in detecting early glaucomatous damage (Uchida et al., 1996; Blumenthal and Weinreb, 2001). These results indicate that a reduction in ONH vaso-activity assessed by flicker stimulation is associated with early loss of nerve fiber layer in eyes with EOAG.
A number of studies have compared Fonh measurements obtained in normal subjects and in glaucoma patients. Although the results vary considerably between studies (Piltz-Seymour et al.,
2001), Fonh has been found to be reduced in primary open-angle glaucoma patients compared
to normal controls (Michelson et al., 1996; Nicolela et al., 1996; Hafez et al., 2003; Riva et al., 2004b). Furthermore, Fonh also tended to be reduced in the OHT patients (Riva et al., 2004b).
The decrease of Fonh in glaucoma has been interpreted by a number of investigators as evidence of an actual reduction in blood flow, although some caution about the validity of this interpretation has been expressed in view of the limitations of the LDF technique. As discussed elsewhere (Riva and Petrig, 2003), comparisons between Fonh values in terms of actual blood flow are strictly valid only if the scattering properties of
the tissue from which Fonh is measured are identical. This is due to the fact that the DSPS depends not only upon the number and velocity of RBCs in the sampled volume, but also on the optical characteristics (i.e. the absorption and scattering) of the tissue (nonmoving scatterers) sampled. In general, increased tissue scattering broadens the power spectrum, causing an artificial increase in the measured flow. To our present knowledge, it is not clear yet how the scattering of light by the glaucomatous rim tissue differs from that of the healthy eye and therefore how it may
affect Fonh.
In contrast to Fonh, RFonh is not affected by the scattering properties of the tissue. Changes in light
scattering may be expected during increased neural activity, but these changes are too fast and probably too small to have a notable effect on
the LDF spectrum and Fonh (Gratton and Fabiani, 2001). Furthermore, the changes in Fonh are
proportional to the actual flow changes as they are within the range of linearity of the LDF technique (Riva et al., 2000). Both of these aspects make the LDF technique most appropriate to investigate the regulation of Fonh in response to various physiological stimuli.
Using flicker to investigate this regulation offers additional advantages over previously used physiological stimuli such as decreases in ocular perfusion pressure (OPP) achieved by increasing the IOP with a suction cup (Pillunat et al., 1997; Riva et al., 1997), increases in OPP by means of isometric exercises (Movaffaghy et al., 1998), and the breathing of various gas mixtures (Harris et al., 1996). Flicker is not invasive and a more physiological stimulus since modulation of light exposure is the most natural stimulus for the visual system, leaving also the systemic circulation unperturbed.
The LDF measurements were obtained by directing the probing laser beam at the temporal site of the neuro-retinal rim of the optic disk. In humans, as in monkeys (Petrig et al., 1999), LDF is probably predominantly sensitive to blood flow changes occurring only in the most superficial layers (supplied by the retinal circulation) of the optic nerve head. However, regardless of which layer of the optic nerve head circulation was in fact
